JP-2022530989-A5 -

Dates

Publication Date

20230511

Application Date

20200501

Description

Those skilled in the art will be able to recognize or confirm many equivalents to the specific embodiments described herein by means of ordinary experimentation. The scope of the embodiments described herein is not intended to be limited to embodiments for carrying out the invention described above, but rather as described in the appended claims. Those skilled in the art will understand that various changes and modifications to this description can be made without departing from the spirit or scope of the invention, as defined in the following claims.The present invention provides, for example, the following items:(Item 1)Compounds of formula I-I:or a pharmaceutically acceptable salt thereof, in the formula,X is selected from the group consisting of NH, O, and S, and the hydrogen of NH is R3It can be replaced by,Y is selected from N and CH, and the hydrogen of CH is R3It can be replaced by,Z is selected from N and CH, and the hydrogen of CH is R3It can be replaced by -C(O)N(R2)- If it is replaced by a part, then Z is C,R1However, C substituted with -Cl, -F, and one or more substituents independently selected from -Cl and -F1-6Selected from the group consisting of alkyl groups,R2However, it is hydrogen,Each R3However, halogen, C1-6Alkyl, C1-6Heteroalkyl, C3-7Cycloalkyl, 3-7 membered heterocyclyl, -S(O)2NR4R5, -NR4S(O)R6, -C(O)NR4R5, -S(O)2R6, and -O-R6Independently selected from the group consisting of C1-6alkyl, halogen, -NR4R5, and -S(O)2R6It is optionally substituted with one or more substituents independently selected from the original,n is selected from the group consisting of 0, 1, 2, 3, and 4.R4and R5However, each independently, hydrogen or C1-6It is alkyl, C1-6Alkyl is optionally substituted with an oxo, or R4and R5However, R4and R5Together with the nitrogen atom to which it is bonded, it forms halogens, -OH, and C1-6Alkyl and C1-6It can form 4- to 7-membered heterocyclines that are optionally substituted with one or more substituents independently selected from the heteroalkyl group.Each R6However, C1-6Alkyl, C1-6Heteroalkyl, C2-6Alkenil, C2-6Alkinyl, C3-7Independently selected from the group consisting of cycloalkyl, phenyl, and benzyl,A compound of formula I-I or a pharmaceutically acceptable salt thereof, wherein s is 1 or 2.A pharmaceutical composition comprising a pharmaceutically acceptable excipient.(Item 2)A pharmaceutical composition as described in item 1, wherein x is NH.(Item 3)A pharmaceutical composition as described in item 1, wherein x is O.(Item 4)A pharmaceutical composition as described in item 1, wherein x is S.(Item 5)A pharmaceutical composition according to any one of items 1 to 4, wherein Y is N.(Item 6)A pharmaceutical composition according to any one of items 1 to 4, wherein Y is CH.(Item 7)A pharmaceutical composition according to any one of items 1 to 6, wherein Z is N.(Item 8)A pharmaceutical composition according to any one of items 1 to 6, wherein Z is CH.(Item 9)The aforementioned compound is a compound of formula I-Ia or formula I-Ia1:or pharmaceutically acceptable salts thereof, the pharmaceutical composition described in item 1, wherein the variables are as defined in item 1.(Item 10)The compound is a compound of formula I-Ib or formula I-Ib1:or pharmaceutically acceptable salts thereof, the pharmaceutical composition according to item 1 or 9, wherein the variables are as defined in item 1.(Item 11)The aforementioned compound is a compound of formula I-a or formula I-a1:or pharmaceutically acceptable salts thereof, the pharmaceutical composition according to item 1 or 9, wherein the variables are as defined in item 1.(Item 12)The compound is a compound of formula I-Ic or formula I-Ic1:or pharmaceutically acceptable salts thereof, the pharmaceutical composition described in item 1, wherein the variables are as defined in item 1.(Item 13)The compound is a compound of formula I-c or formula I-c1:or pharmaceutically acceptable salts thereof, the pharmaceutical composition described in item 1, wherein the variables are as defined in item 1.(Item 14)The compound is a compound of formula I-d or formula I-d1:or pharmaceutically acceptable salts thereof, the pharmaceutical composition according to any one of items 1, 9, and 11, wherein the variables are as defined in item 1.(Item 15)R1However, -Cl, -F, and -CF3A pharmaceutical composition according to any one of items 1 to 14, selected from the group consisting of the following.(Item 16)R1A pharmaceutical composition according to any one of items 1 to 15, wherein -Cl.(Item 17)R1A pharmaceutical composition according to any one of items 1 to 15, wherein the compound is -F.(Item 18)R1However, -CF3A pharmaceutical composition as described in any one of items 1 to 15.(Item 19)Each R3However, -Cl, methyl, -NR4R5or -S(O)2R6Methyl, methoxymethyl, trifluoromethyl, ethyl, cyclopropyl, cyclohexyl, -S(O) substituted2R6, -C(O)NR4R5, and -S(O)2NR4R5A pharmaceutical composition according to any one of items 1 to 18, selected from the gro